Solid Biosciences (SLDB) Payables (2017 - 2026)
Quarterly results put Payables at $5.6 million for Q1 2026, down 13.6% from a year ago — trailing twelve months through Mar 2026 was $5.6 million (down 13.6% YoY), and the annual figure for FY2025 was $3.2 million, down 23.91%.
Solid Biosciences has reported Payables over the past 10 years, most recently at $5.6 million for Q1 2026.
- Payables reached $5.6 million in Q1 2026 per SLDB's latest filing, up from $3.2 million in the prior quarter.
- Across five years, Payables topped out at $8.4 million in Q3 2025 and bottomed at $1.7 million in Q1 2024.
- Median Payables over the past 5 years was $4.2 million (2024), compared with a mean of $4.2 million.
- The largest annual shift saw Payables plummeted 69.08% in 2024 before it surged 272.2% in 2025.
- Over 5 years, Payables stood at $3.2 million in 2022, then crashed by 37.25% to $2.0 million in 2023, then skyrocketed by 108.51% to $4.2 million in 2024, then fell by 23.91% to $3.2 million in 2025, then surged by 72.55% to $5.6 million in 2026.
- Business Quant data shows Payables for SLDB at $5.6 million in Q1 2026, $3.2 million in Q4 2025, and $8.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.03 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | 5.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 3.22 Mn |
| Sep 30, 2025 | 8.43 Mn |
| Jun 30, 2025 | 4.70 Mn |
| Mar 31, 2025 | 6.44 Mn |
| Dec 31, 2024 | 4.24 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 2.52 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 2.03 Mn |
| Sep 30, 2023 | 1.90 Mn |
| Jun 30, 2023 | 2.97 Mn |
| Mar 31, 2023 | 5.60 Mn |
| Dec 31, 2022 | 3.24 Mn |
| Sep 30, 2022 | 5.15 Mn |
| Jun 30, 2022 | 5.11 Mn |
| Mar 31, 2022 | 4.76 Mn |
| Dec 31, 2021 | 4.46 Mn |
| Sep 30, 2021 | 4.15 Mn |
| Jun 30, 2021 | 3.00 Mn |
| Mar 31, 2021 | 3.19 Mn |
| Dec 31, 2020 | 3.27 Mn |
| Sep 30, 2020 | 4.08 Mn |
| Jun 30, 2020 | 2.79 Mn |
| Mar 31, 2020 | 2.38 Mn |
| Dec 31, 2019 | 7.12 Mn |
| Sep 30, 2019 | 3.21 Mn |
| Jun 30, 2019 | 5.60 Mn |
| Mar 31, 2019 | 5.35 Mn |
| Dec 31, 2018 | 3.69 Mn |
| Sep 30, 2018 | 4.80 Mn |
| Jun 30, 2018 | 3.74 Mn |
| Mar 31, 2018 | 5.84 Mn |
| Dec 31, 2017 | 5.07 Mn |